LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$101.71 USD
+3.08 (3.12%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $101.68 -0.03 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.71 USD
+3.08 (3.12%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $101.68 -0.03 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
Zacks News
Earnings Preview: LeMaitre Vascular (LMAT) Q2 Earnings Expected to Decline
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trump Pushes for US-Made Medical Products: 4 Winners
by Ritujay Ghosh
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
LeMaitre Vascular (LMAT) Meets Q1 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -2.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: LeMaitre Vascular (LMAT) Q1 Earnings Expected to Decline
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens U.S. Retail Pharmacy Rises Amid Reimbursement Woes
by Zacks Equity Research
Intensifying competition in the U.S. retail drugstore market prompts Walgreens Boots (WBA) to diversify its product offerings.
LabCorp (LH) Rides on Solid Diagnostics Despite PAMA Issues
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development delivers organic growth despite foreign currency headwind.
Here's Why You Should Add Zimmer (ZBH) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.
Hologic Expands Panther Portfolio With New Product Offerings
by Zacks Equity Research
Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.
LeMaitre Vascular (LMAT) Q4 Earnings Match Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -1.05%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed's (RMD) performance.
LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 19.05% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.
Here's Why You Should Add Abbott (ABT) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.
Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
by Zacks Equity Research
Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.
NuVasive's New TLIF Implant Broadens Spine Surgery Option
by Zacks Equity Research
NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.
National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.
Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View
by Zacks Equity Research
Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.
Moving Average Crossover Alert: LeMaitre Vascular
by Zacks Equity Research
LeMaitre Vascular, Inc. (LMAT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.